Celea Therapeutics Hires New Chief Medical Officer
The Boston-based biopharma firm adds executive depth as it advances its Phase 3 idiopathic pulmonary fibrosis trial.
Updated on Oct. 29, 2026 in People
Live Poll
Do you trust executive leadership changes to improve long-term outcomes for new medical treatments?
Boston-based biopharmaceutical company Celea Therapeutics has appointed Paul Audhya as its new Chief Medical Officer. The leadership change comes as the clinical-stage firm advances its Phase 3 trial for idiopathic pulmonary fibrosis.
Why it matters
The hire is designed to bolster the executive team as Celea Therapeutics transitions into a more advanced stage of clinical development following its recent $180 million financing round. Securing experienced leadership is a critical operational milestone for biotech firms managing high-stakes, late-stage drug trials.
The firm recently secured $180 million in financing in July 2026 to support its research efforts. The leadership expansion follows this capital raise and includes newly filled roles for a Chief Financial Officer, Chief Operating Officer, and General Counsel.
The players
Paul Audhya
The new Chief Medical Officer brings three decades of clinical development experience to the Boston-based biotech firm.
Celea Therapeutics
A Boston-based clinical-stage biopharmaceutical company that spun off from PureTech Health to develop deupirfenidone.
The details
Paul Audhya, who holds an MD and an MBA, will lead Celea's clinical development and medical strategy. His primary focus is the advancement of deupirfenidone, an investigational oral antifibrotic therapy currently being evaluated in the Phase 3 SURPASS-IPF trial. The company, which spun off from PureTech Health, is scaling its internal operations to support the complex requirements of late-stage clinical development.
Timeline
July 2026: Celea Therapeutics closed $180 million in financing.
October 29, 2026: Paul Audhya was appointed as Chief Medical Officer.
Market Landscape
The appointment of a new medical lead for the Phase 3 SURPASS-IPF trial follows a established trend of biotech firms scaling operations post-financing. This move mirrors the staffing patterns of other clinical-stage companies preparing for the resource-heavy demands of late-stage development.
Operators in the biotech sector should track how Celea Therapeutics integrates this new leadership to meet its Phase 3 development milestones. Managing the transition from early-stage funding to late-stage trial execution remains a key indicator of long-term operational success.
The takeaway
Building out a C-suite with specific medical and financial expertise is a hallmark of successful scaling in the biopharmaceutical industry. Operators should monitor whether the new leadership team maintains the current trial timeline for deupirfenidone throughout the coming year.
Further reading
For more on executive changes in the region, visit Boston People.
Live Poll
Do you trust executive leadership changes to improve long-term outcomes for new medical treatments?
